Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Chang Y-L, Wu C-T, Lin S-C, Hsiao C-F, Jou Y-S, Lee Y-C. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res. 2007;13(1):52–58. doi:10.1158/1078-0432.CCR-06-174317200338
   PubMed Web of Science ®Google Scholar
• Battafarano RJ, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg. 2002;74(4):988–994. doi:10.1016/S0003-4975(02)03878-X12400733
   PubMed Web of Science ®Google Scholar
• Zuin A, Andriolo LG, Marulli G, et al. Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer? Eur J Cardiothorac Surg. 2013;44(2):e120–e125; discussion e125. doi:10.1093/ejcts/ezt219
   PubMed Web of Science ®Google Scholar
• Stella F, Luciano G, Dell’Amore A, et al. Pulmonary metastases from NSCLC and MPLC (Multiple Primary Lung Cancers): management and outcome in a single centre experience. Heart Lung Circ. 2016;25(2):191–195. doi:10.1016/j.hlc.2015.07.01626525847
   PubMed Web of Science ®Google Scholar
• Mascalchi M, Comin CE, Bertelli E, et al. Screen-detected multiple primary lung cancers in the ITALUNG trial. J Thorac Dis. 2018;10(2):1058–1066. doi:10.21037/jtd.2018.01.9529607181
   PubMed Web of Science ®Google Scholar
• Boyle JM, Tandberg DJ, Chino JP, D’Amico TA, Ready NE, Kelsey CR. Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis. Cancer. 2015;121(4):598–604. doi:10.1002/cncr.2909525283893
   PubMed Web of Science ®Google Scholar
• Yang H, Sun Y, Yao F, et al. Surgical therapy for bilateral multiple primary lung cancer. Ann Thorac Surg. 2016;101(3):1145–1152. doi:10.1016/j.athoracsur.2015.09.02826602007
   PubMed Web of Science ®Google Scholar
• Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg. 2007;134(3):630–637. doi:10.1016/j.jtcvs.2007.06.00117723810
   PubMed Web of Science ®Google Scholar
• Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606–612. doi:10.1016/S0022-5223(19)40289-4170482
   PubMed Web of Science ®Google Scholar
• Benjamin DK, James ML, Frank CD, David RJ. Special treatment issues in non-small cell lung cancer-diagnosis and management of lung cancer, 3rd ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e369S–e399S.23649447
   PubMed Web of Science ®Google Scholar
• Rami-Porta RAH, Travis WD, Rusch VW. AJCC Cancer Staging Manual. 8 ed. France: Springer International Publishing; 2017.
   Google Scholar
• Chen T-F, Xie C-Y, Rao B-Y, et al. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. BMC Surg. 2019;19(1):185. doi:10.1186/s12893-019-0643-031795997
   PubMed Web of Science ®Google Scholar
• Li R, Li X, Xue R, et al. Early metastasis detected in patients with multifocal pulmonary ground-glass opacities (GGOs). Thorax. 2018;73(3):290–292. doi:10.1136/thoraxjnl-2017-21016929056599
   PubMed Web of Science ®Google Scholar
• Su K, Gao S, Ying J, Zou S, He J. Sequencing a super multiple synchronous lung cancer reveals a novel variant in driver gene ARID1B. J Thorac Cardiovasc Surg. 2018;155(6):e185–e191. doi:10.1016/j.jtcvs.2018.01.01029576263
   PubMed Web of Science ®Google Scholar
• Nikitas J, DeWees T, Rehman S, et al. Stereotactic body radiotherapy for early-stage multiple primary lung cancers. Clin Lung Cancer. 2019;20(2):107–116. doi:10.1016/j.cllc.2018.10.01030477740
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS. Special treatment issues. Chest. 2003;123(1):244S–258S. doi:10.1378/chest.123.1_suppl.244S12527583
   PubMed Web of Science ®Google Scholar
• Shen KR, Meyers BF, Larner JM, Jones DR. Special treatment issues in lung cancer - ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3):290S–305S. doi:10.1378/chest.07-138217873175
   PubMed Web of Science ®Google Scholar
• Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705. doi:10.1097/JTO.0b013e31812d05d517762335
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(5):651–665. doi:10.1016/j.jtho.2016.01.02526944304
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi:10.1016/j.chest.2016.10.01027780786
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11(5):639–650.26940528
   PubMed Web of Science ®Google Scholar
• Park E, Ahn S, Kim H, et al. Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass/lepidic nodules. J Thorac Oncol. 2018;13(11):1776–1783. doi:10.1016/j.jtho.2018.07.09730121391
   PubMed Web of Science ®Google Scholar
• Ren YJ, Huang SJ, Dai CY, et al. Germline predisposition and copy number alteration in pre-stage lung adenocarcinomas presenting as ground-glass nodules. Front Oncol. 2019;9:288. doi:10.3389/fonc.2019.0028831058088
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li G, Li Y, et al. Imaging features suggestive of multiple primary lung adenocarcinomas. Ann Surg Oncol. 2019;27(6):2061–2070.31863415
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Suzuki K, Takamochi K, Oh S. New simple radiological criteria proposed for multiple primary lung cancers. Jpn J Clin Oncol. 2017;47(11):1073–1077. doi:10.1093/jjco/hyx11328973259
   PubMed Web of Science ®Google Scholar
• Yu F, Tang J, Liu W, et al. Genetic profiling of synchronous multiple primary lung carcinomas presenting as ground-glass opacities. J Clin Oncol. 2019;37(15_suppl):e20034–e20034. doi:10.1200/JCO.2019.37.15_suppl.e20034
   Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.000000000000063026291008
   PubMed Web of Science ®Google Scholar
• Kadota K, Nitadori J, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol. 2015;10(5):806–814. doi:10.1097/JTO.000000000000048625629637
   PubMed Web of Science ®Google Scholar
• Hara K, Mizuguchi S, Okada S, et al. Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma. Thorac Cancer. 2019;10(4):832–838. doi:10.1111/1759-7714.1300830821130
   PubMed Web of Science ®Google Scholar
• Kadota K, Kushida Y, Kagawa S, et al. Limited resection Is associated with a higher risk of locoregional recurrence than lobectomy in stage I lung adenocarcinoma with tumor spread through air spaces. Am J Surg Pathol. 2019;43(8):1033–1041. doi:10.1097/PAS.000000000000128531107717
   PubMed Web of Science ®Google Scholar
• Eguchi T, Kameda K, Lu S, et al. Lobectomy is associated with better outcomes than sublobar resection in Spread through Air Spaces (STAS)-positive T1 lung adenocarcinoma: a propensity score-matched analysis. J Thorac Oncol. 2019;14(1):87–98. doi:10.1016/j.jtho.2018.09.00530244070
   PubMed Web of Science ®Google Scholar
• Shiono S, Endo M, Suzuki K, Yarimizu K, Hayasaka K, Yanagawa N. Spread through air spaces is a prognostic factor in sublobar resection of non-small cell lung cancer. Ann Thorac Surg. 2018;106(2):354–360. doi:10.1016/j.athoracsur.2018.02.07629625101
   PubMed Web of Science ®Google Scholar
• Dijkman BG, Schuurbiers OCJ, Vriens D, et al. The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging. 2010;37(11):2037–2047. doi:10.1007/s00259-010-1505-220533031
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang Y, Xue Z, et al. SUVmax ratio on PET/CT may differentiate between lung metastases and synchronous multiple primary lung cancer. Acad Radiol. 2020;27(5):618–623. doi:10.1016/j.acra.2019.07.00131787567
   PubMed Web of Science ®Google Scholar
• Suh YJ, Lee HJ, Sung P, et al. A novel algorithm to differentiate between multiple primary lung cancers and intrapulmonary metastasis in multiple lung cancers with multiple pulmonary sites of involvement. J Thorac Oncol. 2020;15(2):203–215. doi:10.1016/j.jtho.2019.09.22131634666
   PubMed Web of Science ®Google Scholar
• Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts H. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500–510. doi:10.1038/s41568-018-0016-529777175
   PubMed Web of Science ®Google Scholar
• Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi:10.1038/s41591-018-0300-730617339
   PubMed Web of Science ®Google Scholar
• Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703–715. doi:10.1038/s41571-019-0252-y31399699
   PubMed Web of Science ®Google Scholar
• Nishio M, Sugiyama O, Yakami M, et al. Computer-aided diagnosis of lung nodule classification between benign nodule, primary lung cancer, and metastatic lung cancer at different image size using deep convolutional neural network with transfer learning. PLoS One. 2018;13(7):e0200721.30052644
   PubMed Web of Science ®Google Scholar
• Nasrullah N, Sang J, Alam MS, Mateen M, Cai B, Hu H. Automated lung nodule detection and classification using deep learning combined with multiple strategies. Sensors (Basel). 2019;19(17):3722.
   PubMed Web of Science ®Google Scholar
• Travis WD, Elizabeth B, Konrad M-H, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
   Google Scholar
• Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol. 2009;33(12):1752–1764. doi:10.1097/PAS.0b013e3181b8cf0319773638
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed., Vol. 7 Lyon, France: International Agency for Research on Cancer; 2015.
   Google Scholar
• Sun W, Feng L, Yang X, et al. Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis. Hum Pathol. 2018;81:261–271. doi:10.1016/j.humpath.2018.01.03030420048
   PubMed Web of Science ®Google Scholar
• Sun W, Liu Y, Liu XY, Lin DM, Lv N. Significance of nonmucinous lepidic component with mild nuclear atypia in the discrimination of multiple primary lung cancers from intrapulmonary metastases. Int J Clin Exp Pathol. 2014;7(11):7583–7596.25550795
   PubMed Web of Science ®Google Scholar
• Matsuzoe D, Hideshima T, Ohshima K, Kawahara K, Shirakusa T, Kimura A. Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer. 1999;79(9–10):1549–1552. doi:10.1038/sj.bjc.669024710188905
   PubMed Web of Science ®Google Scholar
• Iwata T, Sugio K, Uramoto H, et al. Detection of EGFR and K-ras mutations for diagnosis of multiple lung adenocarcinomas. Front Biosci (Landmark Ed). 2011;16:2961–2969. doi:10.2741/389121622214
   PubMed Web of Science ®Google Scholar
• Ikeda K, Nomori H, Ohba Y, et al. Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias. J Thorac Oncol. 2008;3(5):467–471. doi:10.1097/JTO.0b013e31816b4b1418448997
   PubMed Web of Science ®Google Scholar
• Chung J-H, Choe G, Jheon S, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol. 2009;4(12):1490–1495. doi:10.1097/JTO.0b013e3181bc973119844187
   PubMed Web of Science ®Google Scholar
• Takamochi K, Oh S, Matsuoka J, Suzuki K. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer. 2012;75(3):313–320. doi:10.1016/j.lungcan.2011.08.00722209037
   PubMed Web of Science ®Google Scholar
• Patel SB, Kadi W, Walts AE, et al. Next-generation sequencing: a novel approach to distinguish multifocal primary lung adenocarcinomas from intrapulmonary metastases. J Mol Diagn. 2017;19(6):870–880. doi:10.1016/j.jmoldx.2017.07.00628866070
   PubMed Web of Science ®Google Scholar
• Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H. Utility of genomic analysis in differentiating synchronous and metachronous lung adenocarcinomas from primary adenocarcinomas with intrapulmonary metastasis. Transl Oncol. 2017;10(3):442–449. doi:10.1016/j.tranon.2017.02.00928448960
   PubMed Web of Science ®Google Scholar
• Roepman P, Ten Heuvel A, Scheidel KC, et al. Added value of 50-gene panel sequencing to distinguish multiple primary lung cancers from pulmonary metastases: a systematic investigation. J Mol Diagn. 2018;20(4):436–445. doi:10.1016/j.jmoldx.2018.02.00729625247
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Shien K, Tomida S, et al. Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. Cancer Sci. 2018;109(11):3634–3642. doi:10.1111/cas.1379730216592
   PubMed Web of Science ®Google Scholar
• Chang JC, Alex D, Bott M, et al. Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic approach. Clin Cancer Res. 2019;25(23):7113–7125. doi:10.1158/1078-0432.CCR-19-170031471310
   PubMed Web of Science ®Google Scholar
• Donfrancesco E, Yvorel V, Casteillo F, et al. Histopathological and molecular study for synchronous lung adenocarcinoma staging. Virchows Arch. 2020;476(6):835–842. doi:10.1007/s00428-019-02736-031900636
   PubMed Web of Science ®Google Scholar
• Higuchi R, Nakagomi T, Goto T, et al. Identification of clonality through genomic profile analysis in multiple lung cancers. J Clin Med. 2020;9(2):573. doi:10.3390/jcm9020573
   PubMed Web of Science ®Google Scholar
• Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med. 2012;4(127):127ps110. doi:10.1126/scitranslmed.3003854
   Web of Science ®Google Scholar
• Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875–4882. doi:10.1158/0008-5472.CAN-12-221723002210
   PubMed Web of Science ®Google Scholar
• Mansuet-Lupo A, Barritault M, Alifano M, et al. Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J Thorac Oncol. 2019;14(5):844–856. doi:10.1016/j.jtho.2019.01.01730721797
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang JJ, Li L, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 2016;7:13200. doi:10.1038/ncomms1320027767028
   PubMed Web of Science ®Google Scholar
• Ma P, Fu Y, Cai MC, et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. 2017;8(1):823. doi:10.1038/s41467-017-00963-029018192
   PubMedGoogle Scholar
• Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577–586.29968853
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Harris FR, Kosari F, et al. Using genomics to differentiate multiple primaries from metastatic lung cancer. J Thorac Oncol. 2019;14(7):1567–1582. doi:10.1016/j.jtho.2019.05.00831103780
   PubMedGoogle Scholar
• Murphy SJ, Aubry MC, Harris FR, et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. J Clin Oncol. 2014;32(36):4050–4058. doi:10.1200/JCO.2014.56.764425385739
   PubMed Web of Science ®Google Scholar
• Shen C, Wang X, Tian L, et al. “Different trend” in multiple primary lung cancer and intrapulmonary metastasis. Eur J Med Res. 2015;20(1):17. doi:10.1186/s40001-015-0109-525889108
   PubMedGoogle Scholar
• Tian L, Wang X, Zeng RJ, et al. Microsatellite alteration in plasma DNA discriminates multiple primary lung cancer from metastatic lung cancer. Transl Cancer Res. 2017;6(4):720–731. doi:10.21037/tcr.2017.07.07
   Web of Science ®Google Scholar
• Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101(8):560–570. doi:10.1093/jnci/djp05419351924
   PubMed Web of Science ®Google Scholar
• Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in cancer. Essays Biochem. 2019;63(6):797–811.31845735
   PubMed Web of Science ®Google Scholar
• Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777–786. doi:10.1016/S0140-6736(18)31268-630100054
   PubMed Web of Science ®Google Scholar
• Sano A, Kage H, Sugimoto K, et al. A second-generation profiling system for quantitative methylation analysis of multiple gene promoters: application to lung cancer. Oncogene. 2007;26(45):6518–6525. doi:10.1038/sj.onc.121048317452971
   PubMed Web of Science ®Google Scholar
• Wu L, Kang P, Tao S, et al. Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report. BMC Med Genomics. 2020;13(1):15.32005243
   PubMed Web of Science ®Google Scholar
• Ono K, Sugio K, Uramoto H, et al. Discrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer-related proteins. Cancer. 2009;115(15):3489–3500. doi:10.1002/cncr.2438219452548
   PubMed Web of Science ®Google Scholar
• Chen DL, Mei LY, Zhou YB, et al. A novel differential diagnostic model for multiple primary lung cancer: differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis. Oncol Lett. 2015;9(3):1081–1088. doi:10.3892/ol.2015.288025663860
   PubMed Web of Science ®Google Scholar
• Rea F, Zuin A, Callegaro D, Bortolotti L, Guanella G, Sartori F. Surgical results for multiple primary lung cancers. Eur J Cardiothorac Surg. 2001;20(3):489–495. doi:10.1016/S1010-7940(01)00858-211509268
   PubMedGoogle Scholar
• Aziz TM, Saad RA, Glasser J, Jilaihawi AN, Prakash D. The management of second primary lung cancers. A single centre experience in 15 years. Eur J Cardiothorac Surg. 2002;21(3):527–533. doi:10.1016/S1010-7940(02)00024-611888775
   PubMed Web of Science ®Google Scholar
• Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg. 2007;133(5):1193–1200. doi:10.1016/j.jtcvs.2007.01.01217467428
   PubMed Web of Science ®Google Scholar
• De Leyn P, Moons J, Vansteenkiste J, et al. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg. 2008;34(6):1215–1222.18829338
   PubMed Web of Science ®Google Scholar
• Rostad H, Strand TE, Naalsund A, Norstein J. Resected synchronous primary malignant lung tumors: a population-based study. Ann Thorac Surg. 2008;85(1):204–209. doi:10.1016/j.athoracsur.2007.07.09118154811
   PubMed Web of Science ®Google Scholar
• Finley DJ, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol. 2010;5(2):197–205. doi:10.1097/JTO.0b013e3181c814c520101145
   PubMed Web of Science ®Google Scholar
• Yu Y-C, Hsu P-K, Yeh Y-C, et al. Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? Ann Thorac Surg. 2013;96(6):1966–1974. doi:10.1016/j.athoracsur.2013.04.14224021769
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Nakayama H, Ito H, et al. Surgical treatment for synchronous primary lung adenocarcinomas. Ann Thorac Surg. 2014;98(6):1983–1988. doi:10.1016/j.athoracsur.2014.07.00625443005
   PubMed Web of Science ®Google Scholar
• Shimada Y, Saji H, Otani K, et al. Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions. Lung Cancer. 2015;88(2):174–180. doi:10.1016/j.lungcan.2015.02.01625758554
   PubMed Web of Science ®Google Scholar
• Dai L, Yang HL, Yan WP, et al. The equivalent efficacy of multiple operations for multiple primary lung cancer and a single operation for single primary lung cancer. J Thorac Dis. 2016;8(5):855–861. doi:10.21037/jtd.2016.03.4227162659
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao S, Mao Y, et al. Surgical outcomes of synchronous multiple primary non-small cell lung cancers. Sci Rep. 2016;6:23252. doi:10.1038/srep2325227254665
   PubMed Web of Science ®Google Scholar
• Cheng H, Lei BF, Peng PJ, Lin YJ, Wang XJ. Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases. J Surg Res. 2017;211:215–222. doi:10.1016/j.jss.2016.11.05028501120
   PubMed Web of Science ®Google Scholar
• Peng Y, Ren W, Wang H, Li M, Feng Z, Peng Z. Surgical treatment is an effective approach for patients with synchronous multiple primary lung cancers. J Cancer Res Ther. 2017;13(4):702–706. doi:10.4103/jcrt.JCRT_140_1728901318
   PubMed Web of Science ®Google Scholar
• Xiao F, Liu D, Guo Y, et al. Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis. J Thorac Dis. 2017;9(4):990–1001. doi:10.21037/jtd.2017.03.5928523154
   PubMed Web of Science ®Google Scholar
• Zhao H, Yang H, Han K, et al. Clinical outcomes of patients with metachronous second primary lung adenocarcinomas. Onco Targets Ther. 2017;10:295–302. doi:10.2147/OTT.S12290828138252
   PubMed Web of Science ®Google Scholar
• Chen H, Fu Q, Sun K. Efficacy and prognosis analysis of surgical treatment for bilateral synchronous multiple primary non-small cell lung cancer. J BUON. 2019;24(6):2245–2252.31983090
   PubMed Web of Science ®Google Scholar
• Kang X, Zhang C, Zhou H, et al. Multiple pulmonary resections for synchronous and metachronous lung cancer at two Chinese centers. Ann Thorac Surg. 2020;109(3):856–863. doi:10.1016/j.athoracsur.2019.09.08831765616
   PubMed Web of Science ®Google Scholar
• Fourdrain A, Bagan P, Georges O, et al. Outcomes after contralateral anatomic surgical resection in multiple lung cancer. Thorac Cardiovasc Surg. 2020.
   PubMed Web of Science ®Google Scholar
• Lee D-S, LaChapelle C, Taioli E, et al. Second primary lung cancers demonstrate similar survival with wedge resection and lobectomy. Ann Thorac Surg. 2019;108(6):1724–1728. doi:10.1016/j.athoracsur.2019.06.02331376378
   PubMed Web of Science ®Google Scholar
• Owen D, Olivier KR, Mayo CS, et al. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiat Oncol. 2015;10:43. doi:10.1186/s13014-015-0340-925889747
   PubMed Web of Science ®Google Scholar
• Usuda J, Ichinose S, Ishizumi T, et al. Management of multiple primary lung cancer in patients with centrally located early cancer lesions. J Thorac Oncol. 2010;5(1):62–68. doi:10.1097/JTO.0b013e3181c4228719952800
   PubMed Web of Science ®Google Scholar
• Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–935. doi:10.1200/JCO.2009.25.092820065181
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(5):295–301. doi:10.1016/j.prro.2017.04.01428596092
   PubMed Web of Science ®Google Scholar
• Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5Suppl):e278S–e313S. doi:10.1378/chest.12-235923649443
   PubMedGoogle Scholar
• Sinha B, McGarry RC. Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. Int J Radiat Oncol Biol Phys. 2006;66(4):1120–1124. doi:10.1016/j.ijrobp.2006.06.04217145532
   PubMed Web of Science ®Google Scholar
• Creach KM, Bradley JD, Mahasittiwat P, Robinson CG. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol. 2012;104(1):19–22. doi:10.1016/j.radonc.2011.12.00522248508
   PubMed Web of Science ®Google Scholar
• Matthiesen C, Thompson JS, De La Fuente Herman T, Ahmad S, Herman T. Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer. J Med Imaging Radiat Oncol. 2012;56(5):561–566. doi:10.1111/j.1754-9485.2012.02393.x23043577
   PubMed Web of Science ®Google Scholar
• Chang JY, Liu YH, Zhu Z, et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013;119(18):3402–3410. doi:10.1002/cncr.2821723798353
   PubMed Web of Science ®Google Scholar
• Griffioen GH, Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol. 2013;107(3):403–408. doi:10.1016/j.radonc.2013.04.02623746675
   PubMed Web of Science ®Google Scholar
• Rahn DA 3rd, Thakur S, Makani S, Sandhu A. Stereotactic body radiation therapy (SBRT) for multiple primary lung cancers (MPLC): a review and case series. J Radiosurg SBRT. 2013;2(2):135–140.29296352
   PubMedGoogle Scholar
• Nishiyama K, Kodama K, Teshima T, Tada H. Stereotactic body radiotherapy for second pulmonary nodules after operation for an initial lung cancer. Jpn J Clin Oncol. 2015;45(10):947–952. doi:10.1093/jjco/hyv11326238818
   PubMed Web of Science ®Google Scholar
• Shintani T, Masago K, Takayama K, et al. Stereotactic body radiotherapy for synchronous primary lung cancer: clinical outcome of 18 cases. Clin Lung Cancer. 2015;16(5):e91–e96. doi:10.1016/j.cllc.2014.12.01125659504
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Yamazaki T, Sato S, et al. Surgery or stereotactic body radiotherapy for metachronous primary lung cancer? A propensity score matching analysis. Gen Thorac Cardiovasc Surg. 2020. doi:10.1007/s11748-020-01394-3
   Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.1105831454018
   PubMed Web of Science ®Google Scholar
• Wu CY, Zhao C, Yang Y, et al. High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thorac Oncol. 2015;10(5):778–783. doi:10.1097/JTO.000000000000048725629635
   PubMed Web of Science ®Google Scholar
• Liu M, He WX, Song N, Yang Y, Zhang P, Jiang GN. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. Eur J Cardiothorac Surg. 2016;50(5):909–913. doi:10.1093/ejcts/ezw11327032467
   PubMedGoogle Scholar
• Yang Y, Yin W, He W, et al. Phenotype-genotype correlation in multiple primary lung cancer patients in China. Sci Rep. 2016;6(1):36177. doi:10.1038/srep3617727796337
   PubMedGoogle Scholar
• Ye C, Wang J, Li W, Chai Y. Novel strategy for synchronous multiple primary lung cancer displaying unique molecular profiles. Ann Thorac Surg. 2016;101(2):e45–e47. doi:10.1016/j.athoracsur.2015.06.04226777970
   PubMed Web of Science ®Google Scholar
• Ryoo BY, Na II, Yang SH, Koh JS, Kim CH, Lee JC. Synchronous multiple primary lung cancers with different response to gefitinib. Lung Cancer. 2006;53(2):245–248. doi:10.1016/j.lungcan.2006.05.01016787685
   PubMed Web of Science ®Google Scholar
• Bao Y, Wu J, Zhang J, Yu Y. Diagnosis and treatment of synchronous multiple primary lung cancer - a case report. Onco Targets Ther. 2019;12:4281–4285. doi:10.2147/OTT.S18331931213845
   PubMed Web of Science ®Google Scholar
• Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B. 2019;9(5):871–879. doi:10.1016/j.apsb.2019.03.00231649840
   PubMed Web of Science ®Google Scholar
• Sun F, Xi J, Zhan C, et al. Ground glass opacities: imaging, pathology, and gene mutations. J Thorac Cardiovasc Surg. 2018;156(2):808–813. doi:10.1016/j.jtcvs.2018.02.11029753514
   PubMed Web of Science ®Google Scholar
• Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019;75:39–51. doi:10.1016/j.ctrv.2019.03.00430954906
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129. doi:10.1186/s12943-018-0864-330139382
   PubMed Web of Science ®Google Scholar
• Tokuyasu H, Horie M, Ishikawa S, Sakai H, Miura H, Yamasaki A. Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: a case report. Respir Med Case Rep. 2020;29:100976.31886125
   PubMed Web of Science ®Google Scholar
• Haratake N, Toyokawa G, Takada K, et al. Programmed death-ligand 1 expression and EGFR mutations in multifocal lung cancer. Ann Thorac Surg. 2018;105(2):448–454. doi:10.1016/j.athoracsur.2017.09.02529254651
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Murphy SJ, Peikert T, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 2016;22(9):2177–2182. doi:10.1158/1078-0432.CCR-15-224626667490
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.30610226
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ambrogio C, Mitsudomi T. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. Transl Lung Cancer Res. 2018;7(4):487–497. doi:10.21037/tlcr.2018.07.0430225212
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. doi:10.1093/annonc/mdz16731125062
   PubMed Web of Science ®Google Scholar